Please ensure Javascript is enabled for purposes of website accessibility

Patient dosed with drug made with RoosterBio’s technology

A human patient has been dosed for the first time with a drug that was made using a Frederick cell manufacturing platform company’s technology.

RoosterBio Inc. announced that its CliniControl cell and media systems were used to make the drug for clinical research by a customer it would not identify to The Daily Record.

It’s the first time standardized off-the-shelf cellular materials and associated scalable biomanufacturing has been used in regenerative medicine therapeutic products, according to RoosterBio.

Margot Connor, CEO of RoosterBio, said in a news release that the development will fuel the rapid commercialization of scalable regenerative cures.

The company now has five customers that the FDA has authorized to cross-reference Roosterbio’s master files for the system as they develop their own products. That lets them simplify  and quicken product development, the company said.

 


To purchase a reprint of this article, contact reprints@thedailyrecord.com.